Patent US4438139A successfully refreshed from Google Patents.
US4438139A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Polymeric diffusion matrix containing estrogens
Assignee: Key Pharmaceuticals Inc
•
Filing: 1982-01-04
•
Granted: 1984-03-20
•
Expires: 2002-01-04
Abstract
Abstract A polymeric diffusion matrix for the sustained release, intravaginal administration of an estrogen is provided. The matrix consists of polyvinylalcohol, polyvinylpyrrolidone and a polar plasticizer.
Inventors
- 👤 Alec D. Keith
- 👤 Wallace Snipes
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 09:35
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7084; A61K31/00; A61K31/13; A61K31/135; A61K31/33; A61K31/395; A61K31/41; A61K31/415; A61K31/56; A61K31/565; A61K9/0012; A61K9/0034; A61K9/0036
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
84 words
A self-supporting polymeric diffusion matrix for the sustained release of a pharmacologically acceptable estrogen in order to deliver said estrogen to a patient and provide said patient with a uterine wall maintenance effect, said matrix comprising from about 1 to about 60% of a polar plasticizer, from about 6 to about 30% by weight polyvinylalcohol, from about 2 to about 30% by weight polyvinylpyrrolidone, and a pharmaceutically effective amount of the estrogen to provide a sustained release of said estrogen over a prolonged period.
Claim 2
Dependent Claim
84 words
A self-supporting polymeric diffusion matrix for the sustained release of a pharmacologically acceptable estrogen in order to deliver said estrogen to a patient and provide said patient with a uterine wall maintenance effect, said matrix comprising from about 1 to about 60% of a polar plasticizer, from about 6 to about 30% by weight polyvinylalcohol, from about 2 to about 30% by weight polyvinylpyrrolidone, and a pharmaceutically effective amount of the estrogen to provide a sustained release of said estrogen over a prolonged period.
Claim 3
Dependent Claim
31 words
The polymeric diffusion matrix of claim 1, wherein the total content of polyvinylalcohol and polyvinylpyrrolidone is from about 25% to about 50% by weight, based on the weight of the matrix.
Claim 4
Dependent Claim
13 words
The polymeric diffusion matrix of claim 1 wherein said polar plasticizer is glycerol.
Claim 5
Dependent Claim
20 words
The polymeric diffusion matrix of claim 3 wherein said polyvinylalcohol has a molecular weight of about 50,000 to about 150,000.
Claim 6
Dependent Claim
19 words
The polymeric diffusion of claim 3 wherein said polyvinylalcohol has a molecular weight of about 100,000 to about 150,000.
Claim 7
Dependent Claim
21 words
The polymeric diffusion matrix of claim 3 wherein said polyvinylpyrrolidone has a molecular weight of from about 15,000 to about 85,000.
Claim 8
Dependent Claim
20 words
The polymeric diffusion matrix of claim 3 wherein said polyvinylpyrrolidone has a molecular weight of about 20,000 to about 60,000.
Claim 9
Dependent Claim
25 words
The polymeric diffusion matrix of claim 1 wherein said polar plasticizer is polyethylene glycol present in an amount of about 1 to about 15% weight.
Claim 10
Dependent Claim
40 words
The polymeric diffusion matrix of claim 1 wherein said polar plasticizer is a mixture of glycerol and polyethylene glycol wherein said polyethylene glycol is present in an amount by weight of from about 1 to 5 parts per weight glycerol.
Claim 11
Dependent Claim
27 words
The polymeric diffusion matrix of claim 1, wherein the estrogen is selected from the group consisting of estrone, estradiol, estriol and their pharmaceutically acceptable esters and derivatives.
Claim 12
Dependent Claim
18 words
The polymeric diffusion matrix of claim 10, wherein the estrogen is estradiol 3-benzoate, estradiol 3-valerate or estradiol diacetate.
Claim 13
Dependent Claim
15 words
The polymeric diffusion matrix of claim 1, further comprising a pharmocologically effective amount of progesterone.
Claim 14
Dependent Claim
45 words
The polymeric diffusion matrix of claim 1, comprising about 20% by weight polyvinylalcohol of molecular weight about 115,000, about 15% by weight of polyvinylpyrrolidone of molecular weight about 40,000, about 5% by weight polyethyleneglycol of molecular weight about 4000 and about 3% by weight glycerol.
References Cited (Backward Citations)
US2138751A
Cited
US2155658A
Cited
US2160503A
Cited
US2127896A
Cited
US2340866A
Cited
US2491642A
Cited
US2693438A
Cited
GB933668A
Cited
US3287222A
Cited
FR1505318A
Cited
SU219116A1
Cited
FR2245161A6
Cited
US4210633A
Cited
US4291014A
Cited
US4321252A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-03-20 | 1987-09-19 | 1988-03-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-03-20 | 1991-09-19 | 1992-03-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-03-20 | 1995-09-19 | 1996-03-20 | $7700.00 | Window Closed / Lapsed |